Clinical analysis, treatment patterns, and long-term outcomes of Hepatocellular carcinoma in Thailand: A multidisciplinary approach
DOI:
https://doi.org/10.62992/tv34rg34Keywords:
HCC, Liver cancer, Mortality, Payment, Treatment modalitiesAbstract
Background: Liver cancer, particularly hepatocellular carcinoma (HCC), is the most prevalent cancer in Thailand and globally. However, comprehensive hospital-based survival data remains limited.
Objectives: The study aimed to ascertain the prevalence, impact of treatment modalities on survival among hepatocellular carcinoma (HCC) patients, and reasons for long-term survival.
Methods: A retrospective study was conducted using medical records of 1,221 HCC patients aged ≥18 years from January 2014 to December 2018. Data were extracted from electronic health records using ICD-10 code C22.0. Long-term survival was defined as surviving ≥5 years. Cox proportional hazard regression analysed clinical characteristics and mortality risk.
Results: A total of 1,221 HCC patients were analysed, with 80.80% mortality during follow-up and median survival of 1.25 years (95%CI: 1.09-1.37). The 5-year and 10-year survival rates were 22.6% (95%CI: 20.30-24.99) and 10.92% (95%CI: 8.84-13.25), respectively. Multivariable analysis showed better survival for females (adjusted HR=0.82; 95%CI: 0.69-0.97) and poorer outcomes with bilateral involvement versus right lobe (adjusted HR=1.34; 95%CI: 1.11-1.62). Surgical resection yielded the highest 5-year survival (58.48%; 95%CI: 52.44-64.03) compared to other treatments, while 29.5% received no treatment.
Conclusion: Surgical resection provided superior survival outcomes. Female gender, right lobe tumour location, and Civil Servant Medical Benefit Scheme (CSMBS) coverage were favourable prognostic factors. Enhanced multidisciplinary care integration is essential to improve treatment accessibility and survival outcomes.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72(2):250-61.
Sangrajrang S, Laversanne M, Bausom R, Mery L, Bray F. Cancer incidence and cancer control in Bangkok, Thailand: Results from the cancer registry 2011-15 and projections to 2035. Cancer Epidemiol. 2020;67:101765.
Imsamran W, Pattatang A, Supaattagorn P, Chiawiriyabunya I, Namthaisong K, Wongsena M, et al. Cancer in Thailand Vo. IX 2013-2015. 2018;IX.
Chitapanarux T, Phornphutkul K. Risk Factors for the Development of Hepatocellular Carcinoma in Thailand. J Clin Transl Hepatol. 2015;3(3):182-8.
Mokdad AA, Hester CA, Singal AG, Yopp AC. Management of hepatocellular in the United States. Chin Clin Oncol. 2017;6(2):21.
Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96(9):e5904.
Wu KT, Wang CC, Lu LG, Zhang WD, Zhang FJ, Shi F, et al. Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities. World J Gastroenterol. 2013;19(23):3649-57.
Yeesoonsang S, McNeil E, Virani S, Bilheem S, Pittayawonganon C, Jiraphongsa C, et al. Trends in Incidence of Two Major Subtypes of Liver and Bile Duct Cancer: Hepatocellular Carcinoma and Cholangiocarcinoma in Songkhla, Southern Thailand, 1989-2030. J Cancer Epidemiol. 2018;2018:8267059.
Fritz A PC, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2013.
Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-93.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.
Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer. 2021;21(1):1157.
Fei FR, Hu RY, Gong WW, Pan J, Wang M. Analysis of Mortality and Survival Rate of Liver Cancer in Zhejiang Province in China: A General Population-Based Study. Can J Gastroenterol Hepatol. 2019;2019:1074286.
Kudo M. Management of hepatocellular carcinoma in Japan as a world-leading model. Liver Cancer. 2018;7:134-147
Chonprasertsuk S, Vilaichone RK. Epidemiology and treatment of hepatocellular carcinoma in Thailand. Jpn J Clin Oncol. 2017;47(4):294-7.
Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol. 2008;26(23):3860-6
Suphanchaimat R, Kunpeuk W, Phaiyarom M, Nipaporn S. The Effects of the Health Insurance Card Scheme on Out-of-Pocket Expenditure Among Migrants in Ranong Province, Thailand. Risk Manag Healthc Policy. 2019;12:317-30.
Verplaetse TL, Roberts W, Peltier MR, Zakiniaeiz Y, Burke C, Moore KE, et al. Risk drinking levels and sex are associated with cancer and liver, respiratory, and other medical conditions. Drug Alcohol Depend Rep. 2021;1:100007.
Verplaetse TL, Peltier MR, Roberts W, Burke C, Moore KE, Pittman B, et al. Sex and alcohol use disorder predict the presence of cancer, respiratory, and other medical conditions: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Addict Behav. 2021;123:107055.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001 Sep;35(3):421-30.
Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-2.
Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update. Oncology. 2014;87 Suppl 1:7-21.
Chen TH, Chen CJ, Yen MF, Lu SN, Sun CA, Huang GT, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer. 2002;98(2):257-61.
Ungtrakul T, Mahidol C, Chun-On P, Laohapand C, Siripongsakun S, Worakitsitisatorn A, et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World J Gastroenterol. 2016;22(34):7806-12.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
International Journal of Public Health Asia Pacific (IJPHAP) is licensed under a Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 international (CC BY-NC-ND 4.0) license, unless otherwise stated. Please read our Policies page for more information on Open Access, copyright, and permissions.
